Ose Immunotherapeutics: license agreement with Veloxis Pharmaceuticals
31 January 2022OSE Immunotherapeutics Announced Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc., its Partner in... View Article